Report Highlights

U.S. Medical Simulation: Market Overview

The U.S. medical simulation market was valued at USD 1.92 billion in 2024 and is forecast to reach USD 3.46 billion by 2032. Demand is concentrated in academic medical centres, teaching hospitals and the military health system, with purchasing shaped by accreditation rules rather than discretionary spending. Private firms such as Laerdal Medical, CAE Healthcare and Gaumard Scientific supply most hardware, while public bodies set the standards that determine what gets bought.

Government has shaped the market's form more than its supply. The Accreditation Council for Graduate Medical Education (ACGME) and the Liaison Committee on Medical Education (LCME) require simulation-based assessment, while the Defense Health Agency funds simulation training across military treatment facilities. Private-sector innovation leads in software, with virtual reality procedural trainers from Mentice and Surgical Science gaining share in surgical education, a segment where government mandates remain largely absent.

Policy-Driven Growth in U.S. Medical Simulation

The first mechanism is Medicare graduate medical education funding. Section 126 of the Consolidated Appropriations Act, 2021 added 1,000 Medicare-funded residency positions, and each new programme must satisfy ACGME Common Program Requirements, which mandate competency assessment. Simulation centres capture this demand because hospitals must equip training sites before residents enrol.

The second and third mechanisms are military and nursing mandates. The Defense Health Agency's Joint Trauma System directs trauma simulation training for deployable medical personnel, funded through National Defense Authorization Act appropriations for military medicine. Separately, Health Resources and Services Administration nursing workforce programmes under Title VIII of the Public Health Service Act fund simulation laboratories at nursing schools, expanding purchases beyond academic medical centres.

Regulatory Barriers and Compliance Costs in U.S. Medical Simulation

Manikins and procedural trainers with programmable physiological functions can fall under FDA device classification, requiring manufacturers to follow 21 CFR Part 820 and submit 510(k) premarket notifications for systems with claimed clinical use. The FDA's Center for Devices and Radiological Health administers this process. User fees under the Medical Device User Fee Amendments run into tens of thousands of dollars per standard submission, and review timelines often exceed 90 days.

Accreditation adds a second layer. The Joint Commission requires hospitals to validate equipment and staff competency under its Comprehensive Accreditation Manual, and state nursing boards set limits on how many clinical hours simulation may replace, forcing vendors to maintain multiple curricular documentation sets. Buy American requirements under the Federal Acquisition Regulation apply to Department of Defense and Veterans Affairs purchases, imposing domestic content thresholds on federal orders.

Policy-Created Opportunities in U.S. Medical Simulation

The Department of Veterans Affairs' Office of Academic Affiliations funds trainee placements at VA medical centres, creating procurement for simulators used in affiliated residency programmes. Vendors holding Federal Supply Schedule contracts, administered by the General Services Administration, can sell directly to VA facilities without re-competing each purchase. This pathway favours manufacturers that have already completed FDA registration and domestic content certification.

Telesimulation and remote assessment represent a second opportunity. Medicare telehealth provisions, updated through annual Medicare Physician Fee Schedule rulemaking, have normalised remote clinical assessment, and Joint Commission standards accept simulation-based competency evidence. Vendors offering cloud scenario libraries mapped to ACGME Milestones 2.0 can capture recurring revenue from programmes without capital budgets.

Market at a Glance

Leading Market Participants

• Laerdal Medical
• CAE Healthcare
• Gaumard Scientific
• 3D Systems
• Mentice
• Surgical Science
• Limbs & Things
• Kyoto Kagaku
• Simulaids
• Operative Experience

Regulatory and Policy Environment for U.S. Medical Simulation

The primary legislation governing devices is the Federal Food, Drug, and Cosmetic Act, administered by the FDA's Center for Devices and Radiological Health under 21 CFR Parts 801, 807 and 820. Key compliance requirements include establishment registration, device listing, labelling under 21 CFR Part 801, and quality system controls. The FDA's Quality Management System Regulation, which replaces the Quality System Regulation and aligns with ISO 13485:2016, takes effect on 2 February 2026.

Educational purchasing is governed by ACGME, LCME and Joint Commission standards rather than statute, and by the Patient Safety and Quality Improvement Act of 2005, which protects simulation-based error reporting. Compared with regional peers, the U.S. framework is less prescriptive on device approval than the EU Medical Device Regulation (EU) 2017/745, which requires notified-body review for training manikins with medical claims. It is, however, more fragmented in education than Canada, where Health Canada's Medical Devices Regulations (SOR/98-282) apply nationally while provincial regulators set separate training rules.

Long-Term Policy Outlook for U.S. Medical Simulation

By 2032, the most consequential change will be the expansion of accreditation-linked simulation requirements, as ACGME continues to tie Milestones assessment to simulated performance. Medicare graduate medical education slots under Section 126 will continue to be allocated through annual CMS rulemaking, keeping residency-driven demand on a predictable path. Procurement cycles will therefore remain tied to academic calendars through the forecast period.

Regulatory oversight of digital and AI-enabled simulators will tighten. FDA's Software as a Medical Device guidance and its final guidance on predetermined change control plans will determine whether adaptive training algorithms require premarket review. Vendors that build pre-certified change protocols early will hold a timing advantage over competitors that wait for clearance.